Liege (Belgium) - May 29, 2009, 18:00 CET - OncoMethylome Sciences
(Euronext Brussels: ONCOB, Euronext Amsterdam: ONCOA), today
announced that an additional 24,540 common shares have been issued by
the company in exchange for EUR 110 thousand as the result of the
exercise of warrants by some employees and consultants of the
company. The majority of the exercised warrants were granted in May
2004 and were scheduled to expire in May 2009 if not exercised. As a
result of this transaction, OncoMethylome now has 13,185,614 shares
outstanding.
To download this press release as a PDF, click here: Press release
About OncoMethylome Sciences
OncoMethylome Sciences (Euronext Brussels: ONCOB; Euronext Amsterdam:
ONCOA) is a molecular diagnostics company developing gene methylation
tests to assist physicians in effectively detecting and treating
cancer. Specifically, the company's tests are designed to help the
physician (i) accurately detect cancer in early stages of cancer
development, (ii) predict a patient's response to drug therapy, and
(iii) predict the likelihood of cancer recurrence.
OncoMethylome boasts a broad product development pipeline consisting
of over ten products and a solid partnering record. The company
collaborates with leading international molecular oncology research
centers, such as The Johns Hopkins University, and has a number of
commercial and collaborative partnerships with Veridex LLC, a Johson
& Johnson company, LabCorp, Schering-Plough Corp., GlaxoSmithKline
Biologicals, Abbott, Millipore Corporation's BioScience Division,
EXACT Sciences Corp., Merck KGaA and Qiagen. OncoMethylome's products
are based on methylation technology invented by Johns Hopkins
University (USA).
Established in January 2003, OncoMethylome has offices in Liege and
Leuven (Belgium), in Durham, NC (USA), and in Amsterdam (the
Netherlands).
For more information please contact:
Philip Devine
Tel. +32-479-505-885
ir@oncomethylome.com
www.oncomethylome.com
This press release contains forward-looking statements and estimates
with respect to the anticipated future performance of OncoMethylome
and the market in which it operates. Such statements and estimates
are based on assumptions and assessments of known and unknown risks,
uncertainties and other factors, which were deemed reasonable but may
not prove to be correct. Actual events are difficult to predict, may
depend upon factors that are beyond the Company's control, and may
turn out to be materially different.
This announcement was originally distributed by Hugin. The issuer is
solely responsible for the content of this announcement.
